All In Biotech

Drug Trial Radar · NCT00441103

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Dec 2006

Primary completion

Nov 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Merck KGaA, Darmstadt, GermanyIndustry
Sponsor type
Industry
First posted
Feb 28, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a \[IFN-beta-1a\], RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) at the end of 16 weeks of treatment Secondary: To evaluate the efficacy of RNF by comparing the mean number of combined unique (CU) lesions per scan per subject between the initial 16 weeks of placebo treatment and 24 weeks of RNF treatment in the same subjects, originally randomized to placebo. Primary Endpoints: The primary endpoint is the difference between the number of CU active MRI lesions at Week 16 in the RNF group (Group 1) versus the placebo group (Group 2). Secondary Endpoints: The secondary endpoint is the difference in the mean number of CU active MRI lesions per scan per subject over the following treatment periods: Study Day 1 - Week 16 versus Weeks 17 - 40 for the subjects randomized to Group 2.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • Rebif® New Formulation (IFN-beta-1a, RNF)Drug

    RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.

  • PlaceboDrug

    Matching placebo will be administered subcutaneously three times a week for 16 weeks.

  • Rebif® New Formulation (IFN-beta-1a, RNF)Drug

    RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16Time frame: 16 Weeks
  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 40

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.